Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01337492 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT01337492 is a Early Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT01337492, a Early Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Patients with either histological confirmation or clinical diagnosis who are candidate for orthotopic liver transplant(OLT) will receive Sorafenib 400mg 2 x day (BID) as a neoadjuvant (bridging) treatment until transplant. If patient progresses or falls outside of the Milan criteria on sorafenib patient can be treated per physician's discretion using local therapy. Patient will be followed until 30 days after the orthotopic liver transplant (OLT).
Interventions
- DRUG Nexavar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01337492
The ClinicalTrials.gov registry entry for NCT01337492 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nexavar is the first listed.
NCT01337492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01337492 about?
NCT01337492 is a clinical study titled "Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)". Patients with either histological confirmation or clinical diagnosis who are candidate for orthotopic liver transplant(OLT) will receive Sorafenib 400mg 2 x day (BID) as a neoadjuvant (bridging) treatment until transplant. If patient progresses or falls outside of the Milan criteria on sorafenib pat...
What is the current status of trial NCT01337492?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2010-09. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01337492?
The interventions under investigation include: Nexavar (DRUG).
Who is sponsoring clinical trial NCT01337492?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.